Logo image of STTK

SHATTUCK LABS INC (STTK) Stock Fundamental Analysis

NASDAQ:STTK - Nasdaq - US82024L1035 - Common Stock - Currency: USD

1.37  +0.08 (+6.2%)

After market: 1.39 +0.02 (+1.46%)

Fundamental Rating

3

Overall STTK gets a fundamental rating of 3 out of 10. We evaluated STTK against 572 industry peers in the Biotechnology industry. While STTK has a great health rating, there are worries on its profitability. STTK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

STTK had negative earnings in the past year.
STTK had a negative operating cash flow in the past year.
STTK had negative earnings in each of the past 5 years.
STTK had a negative operating cash flow in each of the past 5 years.
STTK Yearly Net Income VS EBIT VS OCF VS FCFSTTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

STTK's Return On Assets of -66.61% is on the low side compared to the rest of the industry. STTK is outperformed by 63.41% of its industry peers.
STTK's Return On Equity of -77.06% is in line compared to the rest of the industry. STTK outperforms 53.29% of its industry peers.
Industry RankSector Rank
ROA -66.61%
ROE -77.06%
ROIC N/A
ROA(3y)-39.81%
ROA(5y)-36.64%
ROE(3y)-44.91%
ROE(5y)-62.38%
ROIC(3y)N/A
ROIC(5y)N/A
STTK Yearly ROA, ROE, ROICSTTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

STTK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STTK Yearly Profit, Operating, Gross MarginsSTTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STTK has been increased compared to 1 year ago.
The number of shares outstanding for STTK has been increased compared to 5 years ago.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STTK Yearly Shares OutstandingSTTK Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
STTK Yearly Total Debt VS Total AssetsSTTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.33, we must say that STTK is in the distress zone and has some risk of bankruptcy.
STTK has a Altman-Z score (-3.33) which is comparable to the rest of the industry.
STTK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.33
ROIC/WACCN/A
WACC9.44%
STTK Yearly LT Debt VS Equity VS FCFSTTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 7.96 indicates that STTK has no problem at all paying its short term obligations.
The Current ratio of STTK (7.96) is better than 72.11% of its industry peers.
A Quick Ratio of 7.96 indicates that STTK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.96, STTK is in the better half of the industry, outperforming 72.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.96
Quick Ratio 7.96
STTK Yearly Current Assets VS Current LiabilitesSTTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.70% over the past year.
Looking at the last year, STTK shows a very strong growth in Revenue. The Revenue has grown by 380.22%.
The Revenue for STTK have been decreasing by -40.62% on average. This is quite bad
EPS 1Y (TTM)31.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.23%
Revenue 1Y (TTM)380.22%
Revenue growth 3Y-44.95%
Revenue growth 5Y-40.62%
Sales Q2Q%336.88%

3.2 Future

STTK is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.75% yearly.
Based on estimates for the next years, STTK will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y27.72%
EPS Next 2Y23.74%
EPS Next 3Y14.95%
EPS Next 5Y4.75%
Revenue Next Year494.61%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
STTK Yearly Revenue VS EstimatesSTTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
STTK Yearly EPS VS EstimatesSTTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STTK. In the last year negative earnings were reported.
Also next year STTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STTK Price Earnings VS Forward Price EarningsSTTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STTK Per share dataSTTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

STTK's earnings are expected to grow with 14.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.74%
EPS Next 3Y14.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STTK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SHATTUCK LABS INC

NASDAQ:STTK (2/21/2025, 8:00:01 PM)

After market: 1.39 +0.02 (+1.46%)

1.37

+0.08 (+6.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-18 2025-03-18/amc
Inst Owners61.98%
Inst Owner Change-99.39%
Ins Owners1.68%
Ins Owner Change0%
Market Cap65.40M
Analysts76.36
Price Target1.22 (-10.95%)
Short Float %4.73%
Short Ratio9.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.38%
Min EPS beat(2)0.4%
Max EPS beat(2)22.37%
EPS beat(4)4
Avg EPS beat(4)17.73%
Min EPS beat(4)0.4%
Max EPS beat(4)29.26%
EPS beat(8)7
Avg EPS beat(8)10.43%
EPS beat(12)9
Avg EPS beat(12)18.23%
EPS beat(16)12
Avg EPS beat(16)13.98%
Revenue beat(2)2
Avg Revenue beat(2)243.84%
Min Revenue beat(2)137.21%
Max Revenue beat(2)350.48%
Revenue beat(4)4
Avg Revenue beat(4)278.15%
Min Revenue beat(4)137.21%
Max Revenue beat(4)378.4%
Revenue beat(8)7
Avg Revenue beat(8)311.91%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-40%
EPS NQ rev (1m)8.47%
EPS NQ rev (3m)19.26%
EPS NY rev (1m)0%
EPS NY rev (3m)7.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)28.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)92.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.16
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS0.13
BVpS2.02
TBVpS2.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.61%
ROE -77.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.81%
ROA(5y)-36.64%
ROE(3y)-44.91%
ROE(5y)-62.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.96%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.96
Quick Ratio 7.96
Altman-Z -3.33
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)320.96%
Cap/Depr(5y)233.53%
Cap/Sales(3y)612.38%
Cap/Sales(5y)369.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.23%
EPS Next Y27.72%
EPS Next 2Y23.74%
EPS Next 3Y14.95%
EPS Next 5Y4.75%
Revenue 1Y (TTM)380.22%
Revenue growth 3Y-44.95%
Revenue growth 5Y-40.62%
Sales Q2Q%336.88%
Revenue Next Year494.61%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y19.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.93%
EBIT Next 3Y11.92%
EBIT Next 5Y3.91%
FCF growth 1Y38.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30%
OCF growth 3YN/A
OCF growth 5YN/A